These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35289329)

  • 1. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.
    Brastianos PK; Kim AE; Giobbie-Hurder A; Lee EQ; Wang N; Eichler AF; Chukwueke U; Forst DA; Arrillaga-Romany IC; Dietrich J; Corbin Z; Moliterno J; Baehring J; White M; Lou KW; Larson J; de Sauvage MA; Evancic K; Mora J; Nayyar N; Loeffler J; Oh K; Shih HA; Curry WT; Cahill DP; Barker FG; Gerstner ER; Santagata S
    Nat Commun; 2022 Mar; 13(1):1325. PubMed ID: 35289329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
    Nidamanuri P; Drappatz J
    J Neurooncol; 2022 Apr; 157(2):271-276. PubMed ID: 35301639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
    Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
    Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
    Yap TA; Nakagawa K; Fujimoto N; Kuribayashi K; Guren TK; Calabrò L; Shapira-Frommer R; Gao B; Kao S; Matos I; Planchard D; Chatterjee A; Jin F; Norwood K; Kindler HL
    Lancet Respir Med; 2021 Jun; 9(6):613-621. PubMed ID: 33836153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
    Bi WL; Nayak L; Meredith DM; Driver J; Du Z; Hoffman S; Li Y; Lee EQ; Beroukhim R; Rinne M; McFaline-Figueroa R; Chukwueke U; McCluskey C; Gaffey S; Cherniack AD; Stefanik J; Doherty L; Taubert C; Cifrino M; LaFrankie D; Graillon T; Wen PY; Ligon KL; Al-Mefty O; Huang RY; Muzikansky A; Chiocca EA; Santagata S; Dunn IF; Reardon DA
    Neuro Oncol; 2022 Jan; 24(1):101-113. PubMed ID: 34015129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
    Reardon DA; Kim TM; Frenel JS; Simonelli M; Lopez J; Subramaniam DS; Siu LL; Wang H; Krishnan S; Stein K; Massard C
    Cancer; 2021 May; 127(10):1620-1629. PubMed ID: 33496357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
    Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.
    Raghav KP; Stephen B; Karp DD; Piha-Paul SA; Hong DS; Jain D; Chudy Onwugaje DO; Abonofal A; Willett AF; Overman M; Smaglo B; Huey RW; Meric-Bernstam F; Varadhachary GR; Naing A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
    Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.